BioSpace News Archive

According to data published by Hexa Research, the U.S. medical cannabis market size was valued at USD $5.44 Billion in 2016 and is expected to hit USD $19.48 billion by 2024.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced preclinical data on XmAb24306, an IL15/IL15-receptor alpha complex fused to a bispecific XmAb Fc domain (IL15/IL15Rα-Fc) for the treatment of multiple oncology indications

Medical Marijuana, Inc. announced financial results for the quarter and year ending December 31, 2017 and provided an overview of recent operational highlights.

Great Place to Work® and FORTUNE have honored Martin’s Point as one of the 2018 Best Workplaces in Health Care & Biopharma.

Fresenius Medical Care North America (FMCNA) and the American Nephrology Nurses Association (ANNA) announced five recipients of educational scholarships at ANNA’s 2018 National Symposium in Las Vegas.

First-of-its-kind innovative design in the U.S. enhances patient safety by providing best-in-class infection prevention for flexible endoscopes

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced presentations on amyotrophic lateral sclerosis (ALS) at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, April 21-27.

Mercaptor Discoveries was founded to explore the potential of their core research team’s discovery, “captons,” in neuroprotection and to harness the power of these small molecules to treat brain injuries in situ, where the need is most urgent.

New targeted sequencing workflow combines pre-validated content with easy customization and new analysis tools to accelerate variant discovery and screening

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xencor to perform semi-mechanistic PK/PD modeling to analyze Xencor’s XmAb® IL15/IL15Rα-Fc program for the treatment of solid tumors.